
Efficacy of a new intravenous β2-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma
Keywords: Asthma; Beta agonists; Emergency medicine; Pharmacotherapy; AEA; acute exacerbation of asthma; ICU; intensive care unit; FEV; forced expiratory volume; AUC; area under the curve; SAE; serious adverse event; TEAE; treatment-emergent adverse event; ITT; int